Head-to-head · WeighScore
Curve vs Sumbare Wellness
The verdict
Sumbare Wellness takes it — 61.9/100 to 61.7/100, but only just.
Sumbare Wellness grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Langhorne, Pennsylvania telehealth platform selling compounded semaglutide, tirzepatide and a low-dose GLP-1 protocol on one flat $199/month plan, with the price confirmed only after a provider reviews you. Curve is close behind and may still be the better fit — see the factor split below.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Curve | Sumbare Wellness |
|---|---|---|
| WeighScore | 61.7/100 | 61.9/100 |
| Grade | C | C |
| Scorecard rank | #289 | #283 |
| Semaglutide | $175/mo (compounded) | $199/mo (all doses, compounded) |
| Tirzepatide | $225/mo (compounded) | $199/mo (all doses, compounded) |
| Coverage | All 50 states | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #289 · C
Strengths
- Offers both compounded semaglutide and tirzepatide, with every dose priced the same so cost does not rise as you titrate up.
- LegitScript-certified (seal #51079066) and names both its 503A compounding pharmacy, VialsRx, and its provider network, Beluga Health.
- Transparent tiered pricing with a real month-to-month option; consultation, medication, and free expedited shipping included, no membership.
- Available in all 50 states with same-day provider review; no insurance needed and HSA/FSA accepted.
Where it loses points
- Very new (2026 launch) with a thin track record; the site still shows a Webflow template credit and a leftover Cora reference in its Terms.
- The cheapest headline rates ($99 semaglutide / $135 tirzepatide) require a 12-month prepay; true month-to-month is $175 and $225.
- Both product pages currently display an out-of-stock status, so availability may be inconsistent.
- Compounded medications are not FDA-approved or therapeutically equivalent to Ozempic, Wegovy, Mounjaro, or Zepbound.
Graded #283 · C
Strengths
- One flat $199/month price covering medication, provider review and shipping, with no consultation fee and no dose-change surcharge
- Charges nothing if a provider does not approve you
- Offers a deliberate low-dose microdosing protocol aimed at body composition, which most competitors do not break out
- Publishes a named legal entity, a US mailing address and a working phone number
- Pre-screening quiz is short and asks your goal before any medical question
Where it loses points
- Cancellation terms contradict three ways: the homepage says cancel anytime, the Terms say 48 hours notice, the FAQ says 30 days
- Availability is unclear: the homepage counter reads 3 states while the treatment pages say telehealth nationwide, and no state list is published
- Its chart cites placebo-controlled trials of compounded semaglutide and tirzepatide, which do not exist; those trials studied the branded drugs
- No compounding pharmacy is named, and neither 503A nor 503B appears anywhere on the site
- Any returned prescription is charged a $35 disposal fee, and prescription orders cannot be cancelled at all after 24 hours
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.